



Sunday, September 23, 2018

07:00 - 11:00 **Type: Networking Opportunity**
Title: IASLC Foundation Walk supported by Lung Cancer Canada (Ticketed Event)

07:00 - 08:00 **Registration Opens**

08:00 - 09:30 **Shotgun Start**

09:30 - 11:00 **Celebration and Breakfast/Snacks**

07:00 - 12:00 **Type: Symposium**
Title: IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening (Ticketed Session)

Track: Screening and Early Detection
Moderation: John Field, UK; James Mulshine, USA

Objectives:

1. The Symposium will provide a forum for in-depth reviews of the current status of lung cancer screening with internationally recognized experts in a highly interactive setting.
2. Sessions are designed to provide the IASLC Membership with an opportunity to discuss practical issues involved in the lung cancer screening implementation, with Experts in the field.
3. A focus of the forum will also include a review of how related research areas such as molecular-epidemiological biomarkers and sharing of Images and metadata provides a future insight into how lung cancer screening research is developing.

07:00 - 07:30 **Breakfast**

07:30 - 07:35 **Introductions & Welcome**

Session I: The Backbone to our Knowledge on Lung Cancer Screening

07:35 - 07:50 **Lung Cancer Screening: 1999 to Date - What Have We Learnt?**

David Yankelevitz, USA

07:50 - 08:00 **Discussion**

Session II: Future Integration of Biomarkers in the Selection of High Risk Individuals for Lung Cancer Screening

08:00 - 08:50 **The U19 Plans for Integration of Biomarkers into Future Lung Cancer Screening**

Rayjean Hung, Canada; Chris Amos, USA; Paul Brennan, France

08:50 - 09:00 **Discussion**

Session III: European Strategy for the Implementation of Lung Cancer Screening

09:00 - 09:20 **EU Position Statement on Lung Cancer Screening**

Matthijs Oudkerk, Netherlands

09:20 - 09:30 **Discussion**



- 09:30 - 09:50 **Coffee break**
- Session IV: Lung Cancer Screening Requires Infra-Structural Organisation and an Integrated Smoking Cessation Plan**
- 09:50 - 10:05 **Coordination of the Lung Cancer CT Screening Experience**
Joelle Fathi, Sweden
- 10:05 - 10:20 **Integration of Smoking Cessation into Lung Cancer Screening**
Kate Brain, UK
- 10:20 - 10:30 **Discussion**
- 10:30 - 11:30 **Session V: Panel Discussion: Next Steps for Lung Screening?**
Claudia Henschke, USA; Kwun Fong, Australia; Motoyasu Sagawa, Japan; Matthew Callister, UK; Nasser Altorki, USA; Bruce Pyenson, USA; Andrea Borondy Kitts, USA
- 11:30 - 11:50 **Session VI - IASLC Leads the International Collaboration on Data Sharing (IASLC- ELIC-CCTRR)**
John Field, UK; James Mulshine, USA
- 11:50 - 12:00 **Discussion**
- 12:00 - 12:00 **Networking Lunch**

JCSE01

07:30 - 11:15 **Type: Joint IASLC/CSCO/CAALC Session**
Title: Perspectives for Lung Cancer Early Detection

Track: Screening and Early Detection
Moderation: Fred Hirsch, USA; Yi-long Wu, China; Tony Mok, Hong Kong

- 07:30 - 08:00 **JCSE01.01 - Breakfast and Poster Viewing**
- 08:00 - 08:20 **JCSE01.02 - Necessity for Early Detection in Lung Cancer and Initial Attempts for Early Detection**
Annette McWilliams, Australia
- 08:20 - 08:40 **JCSE01.03 - CT Screening for Early Detection (NLST, UKLS, NELSON, ITALUNG, DANTE, Others)**
Matthijs Oudkerk, Netherlands
- 08:40 - 09:00 **JCSE01.04 - Risk Modeling for the Early Detection of Tin Miner Lung Cancer in China**
You-lin Qiao, China
- 09:00 - 09:20 **JCSE01.05 - Biomarkers and Liquid Biopsy for Early Detection of Lung Cancer**
Allen Chan, China
- 09:20 - 09:40 **JCSE01.06 - Incorporating Artificial Intelligence for Early Detection of Lung Cancer**
Jie Hu, China
- 09:40 - 10:00 **JCSE01.07 - Cost Effectiveness and Economic Implication of Lung Cancer Early Detection**
Gilberto De Lima Lopes, USA
- 10:00 - 10:25 **JCSE01.08 - Coffee Break and Poster Viewing**



- 10:25 - 10:35 JCSE01.09 - Abstract Presentation from China Related to Early Detection (1)
- 10:35 - 10:45 JCSE01.10 - Abstract Presentation from China Related to Early Detection (2)
- 10:45 - 11:55 JCSE01.11 - Abstract Presentation from China Related to Early Detection (3)
- 11:55 - 11:05 JCSE01.12 - Discussant Oral Abstracts
- 11:05 - 11:15 JCSE01.13 - Discussant Poster Abstracts
- 11:15 - 11:15 JCSE01.14 - Closing Remarks

08:00 - 11:30 Type: Workshop
 Title: Endoscopic Diagnosis and Staging of Lung Cancer - Interventional Pulmonology Hands-On Workshop (Ticketed Session)

This course will provide participants with understanding of various endoscopic technology utilized in the diagnosis and staging of lung cancer. An introductory didactic session will feature faculty with experience in endobronchial ultrasound (EBUS), endoscopic ultrasound (EUS), radial probe EBUS as well as navigational bronchoscopy. Brief lectures will focus on the methods of EBUS-TBNA, EUS-FNA, radial probe EBUS guided transbronchial biopsy and navigational bronchoscopy guided biopsy of peripheral lung nodules. However the focus of the course will be on hands-on experience with these techniques and the intimate interaction with experienced faculty. The hands-on sessions will provide the participants with opportunities to perform EBUS-TBNA and EUS-FNA using simulated models for nodal assessment and biopsy. Additional stations will feature radial probe EBUS and navigational bronchoscopy for biopsy of peripheral nodules.

Objectives

1. Describe the applications and limitations of EBUS-TBNA for mediastinal staging of lung cancer
2. Understand the approach to complete mediastinal lymph node staging with combined EBUS-TBNA and EUS-FNA
3. Understand the role of radial probe endobronchial ultrasound in the diagnosis of peripheral nodules
4. Understand the various navigational bronchoscopy systems available for diagnosis of peripheral nodules

- 08:00 - 11:30 **Welcome and Introduction**
- 08:00 - 11:30 **EBUS-TBNA - Role in Invasive Mediastinal Staging**
- 08:00 - 11:30 **Combined EBUS/EUS Mediastinal Staging**
- 08:00 - 11:30 **Radial Probe EBUS - Methods and Results**
- 08:00 - 11:30 **Navigational Bronchoscopy**
- 08:00 - 11:30 **Hands-On Session on 6 stations**

**08:00 - 11:15** **Type: Workshop**
Title: Cancer Genomics Workshop (Ticketed Session)

Genomic medicine is revolutionizing patient care. Of all specialties, oncology has been most affected as next-generation sequencing of tumor specimens to find drug-targetable mutations has entered clinical practice. Treatment of lung cancer has been especially impacted by this new testing paradigm. As such, oncologists must be conversant with the fundamental aspects of clinical genomics. Using a case-based, interactive, small-group approach, faculty will review introductory principles related to genomic assays, interpretation of results and application to patient care. The workshop will also include practical hands-on instruction with the use of online genomic pathology tools. As such, participants should bring a tablet or laptop (preferred) if available to facilitate participation in this aspect of the course.

Course faculty:

Ramaswamy Govindan M.D: Director, Section of Medical Oncology, Washington University School of Medicine

Richard Haspel, MD, PhD: Director of Medical Education, Department of Pathology, Beth Israel Deaconess Medical Center

Overall structure:

Each exercise consists of:

1. An instructor-delivered 15-30 minute PowerPoint lecture to relay content needed to undertake the team-based learning (TBL) activity.
2. A 45-60-minute activity consisting of teams of 3-6 participants working together to answer a series of clinically relevant questions including some necessitating the use of online genomic tools.
3. An instructor-delivered 15-30 minute PowerPoint lecture presenting answers to the questions and incorporating a discussion of team responses.

08:00 - 08:15 **Introduction to the Workshop****08:15 - 09:30** **Exercise 1: Cancer Gene Panels: Methods and Application****Objectives:**

1. Describe the process for selecting a cancer gene panel.
2. Describe different methods for detecting DNA variants (targeted PCR vs. Sanger-based vs. NGS-based)
3. Use online tools to interpret the clinical significance of genomic data
4. Determine appropriate clinical trials based on cancer gene panel data

09:30 - 09:45 **Break****09:45 - 11:00** **Exercise 2: Cancer Gene Panels: Result Interpretation and Clinical Utility****Objectives:**

1. Describe key aspects to discuss with patients prior to genomic analyses
2. Describe the process of NGS data analysis
3. Describe the benefits and limitations of integrative genomic analyses for advanced cancer patients
4. Describe the reporting issues related to germline findings
5. Use online tools to interpret the clinical significance of genomic data

11:00 - 11:15 **Questions/Panel Discussion**



YI01

08:00 - 11:30	Type: Young Investigator Session Title: Young Investigators Session Moderation: Jonathan Yeung, Canada; Katy Clarke, UK
08:00 - 08:10	Introduction to the IASLC - Why You Should be a Member Clarissa Mathias, Brazil
08:10 - 08:20	Planning a Career in Lung Cancer - Clinical Trials Roy Herbst, USA
08:20 - 08:30	Planning a Career in Lung Cancer - Science Yolonda Colson, USA
08:30 - 08:40	Planning a Career in Lung Cancer - Bench to Beside
08:40 - 08:50	Planning a Career in Lung Cancer - Education Barbara Melosky, Canada
08:50 - 09:00	Community Oncology Parneet Cheema, Canada
09:00 - 09:10	Making the Most of your Cooperative Group Rolf Stahel, Switzerland
09:10 - 09:30	Panel Discussion
09:30 - 09:45	Break
09:45 - 10:00	Knowing your Statistics Mary Redman, USA
10:00 - 10:15	How to get your Paper Published Alex Adjei, USA
10:15 - 10:30	Writing a Successful Abstract Michael Boyer, Australia
10:30 - 10:45	How to give a Great Presentation Tony Mok, Hong Kong
10:45 - 11:00	How to write a Successful Grant Application Dean Fennell, UK
11:00 - 11:15	Panel Discussion
11:15 - 11:20	Young investigator Experience



11:20 - 11:30 **Getting the most out of WCLC 2018**
Andrea Bezjak, Canada; Gail Darling, Canada; Natasha Leigh, Canada

11:30 - 11:30 **Close**

ISS01

09:45 - 11:15 **Type: Industry Supported Symposia**
Title: Symposium Supported by Takeda: New Insights and Clinical Implications for the Treatment of ALK+ NSCLC

ISS02

11:30 - 13:00 **Type: Industry Supported Symposia**
Title: Symposium Supported by Incyte: Novel Immunotherapy Strategies in Lung Cancer

12:00 - 18:00 **Type: Workshop**
Title: ITONF Workshop: Excellence in Thoracic Oncology Care

12:00 - 12:30 **ITONF Membership Meeting & Luncheon**
Melissa Culligan, USA

12:30 - 13:00 **Keynote Speaker: Lung Cancer and Mesothelioma Nursing Care in Canada**
Massey Nematollahi, Canada

13:00 - 13:30 **Panel Discussion: Managing Hope and Expectations in Thoracic Oncology**
Maria Guerin, UK; Bethany Taylor, UK; Beth Eaby-Sandy, USA

13:30 - 13:50 **Tag, Tweet or Follow: Top Tips for using Social Media in your Clinical Practice**
Liz Darlison, UK

13:50 - 14:15 **UPDATE: Immunotherapy, Targeted Therapy and Combination Therapy Clinical Trials in Lung Cancer and Mesothelioma**
Buerkley Rose, USA; Rebecca Lau, Australia

14:15 - 14:30 **Break**

14:30 - 15:00 **Global Issues in Lung Cancer and Mesothelioma in 2018**
Andrea Serena, Switzerland; Lorraine Creech, UK

15:00 - 15:45 **UPDATE: Advances in Local Treatments for Lung Cancer and Mesothelioma (Radiation and Surgery)**
Mary Duffy, Australia; Jenny Mitchell, UK; Anastasia Bykova, Canada

15:45 - 16:00 **Break**

16:00 - 16:30 **Nurse-led TeleHealth in Thoracic Oncology**
Sarah Cubbin, UK; John Mcphelim, UK



16:30 - 17:00 **UPDATE: Toxicity Management of Immunotherapy Treatments in Lung Cancer and Mesothelioma**
Kathleen Gamblin, USA; John Mcphelim, UK; Anne Fraser, New Zealand; Marianne Davies, USA

17:00 - 17:30 **2017-18 Year in Review: Scientific Poster Session**
Maria Guerin, UK

ISS03

13:00 - 14:30 **Type: Industry Supported Symposia**
Title: Symposium Supported by Lilly Oncology: Driving Improved Outcomes in Non-driver Mutation Lung Cancer: The Challenges and Progress

ISS04

14:30 - 16:00 **Type: Industry Supported Symposia**
Title: Symposium Supported by Bristol-Myers Squibb

ISS05

16:00 - 17:30 **Type: Industry Supported Symposia**
Title: Symposium Supported by AstraZeneca

PR01

16:00 - 17:30 **Type: Press Conference**
Title: Press Conference

17:45 - 18:45 **Type: Networking Opportunity**
Title: IASLC Foundation Concert (Ticketed Event)

The IASLC Foundation is proud to invite you to a benefit concert in support of the IASLC Foundation. This performance is given in honour of those who have been afflicted by lung cancer and those who have dedicated their lives to research, diagnoses, and treatment of the disease.

Concert Information

- Members of the Toronto Symphony Orchestra (TSO)
- Metro Toronto Convention Centre, MTCC, North Building, Room 102 (John Bassett Theatre)
- Tickets: 50 USD, limited seating available

About the IASLC Foundation

The IASLC Foundation supports the International Association for the Study of Lung Cancer (IASLC) to provide fellowships to researchers worldwide and to aid their work in finding new ways to conquer lung cancer and other thoracic malignancies.

The fellowships funded by the IASLC Foundation create a new avenue of support for the IASLC to foster groundbreaking and collaborative research worldwide. The IASLC has provided more than 80 researchers with fellowships since 2000.

The mission of the IASLC Foundation is to support the IASLC in order to:

- Embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment, and all other aspects of lung cancer and other thoracic malignancies;



- Provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public;
- Use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

The Foundation supports researchers, rewards scientific excellence, and encourages innovative research in lung cancer prevention and translational medicine around the world.

OC01

19:00 - 20:30 **Type: Opening Ceremony**
Title: Opening Ceremony

19:00 - 19:10 **OC01.01 - Eradicating Lung Cancer**
Prabat Jha, Canada

19:10 - 19:20 **OC01.02 - Tobacco Free World**
Bronwyn King, Australia

20:30 - 22:00 **Type: Networking Opportunity**
Title: Welcome Reception



Monday, September 24, 2018

ISS06

07:00 - 08:00 **Type: Industry Supported Symposia**
Title: Symposium Supported by Medscape

MTE01

07:00 - 08:00 **Type: Meet the Expert**
Title: Preclinical Models of Lung Cancer (Ticketed Session)
Track: Biology

07:00 - 07:30 **MTE01.01 - GEMM of Lung Cancer**

Sarah Best, Australia

07:30 - 08:00 **MTE01.02 - Lung Patient Derived Xenograft and Organoid**

Nadeem Moghal, Canada

MTE02

07:00 - 08:00 **Type: Meet the Expert**
Title: Update on WHO Classification and Staging of Lung Cancer (Ticketed Session)
Track: Pathology

07:00 - 07:30 **MTE02.01 - Update on WHO Classification and Staging of Lung Cancer**

Sanja Dacic, USA

07:30 - 08:00 **MTE02.02 - Update on WHO Classification and Staging of Lung Cancer**

Teh-Ying Chou, Taiwan

MTE03

07:00 - 08:00 **Type: Meet the Expert**
Title: Clinical Trial Design With Novel Lung Cancer Therapy (Ticketed Session)
Track: Targeted Therapy

07:00 - 07:30 **MTE03.01 - Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)**

Peter Ellis, Canada

07:30 - 08:00 **MTE03.02 - Novel Trial Design for Precision Medicine**

Fiona Blackhall, UK



MTE04

07:00 - 08:00 Type: Meet the Expert
Title: Comparison of Various Risk Models (Ticketed Session)
Track: Screening and Early Detection

07:00 - 07:30 **MTE04.01 - Comparisons of Risk Models**
Christine Berg, USA

07:30 - 08:00 **MTE04.02 - Where Should Health Programs Set Threshold for Tailored Screening?**
James Mulshine, USA

MTE05

07:00 - 08:00 Type: Meet the Expert
Title: Role of Pneumonectomy in N2 Disease (Ticketed Session)
Track: Treatment of Locoregional Disease - NSCLC

07:00 - 07:30 **MTE05.01 - Role of Pneumonectomy in N2 Disease**
Jessica Donington, USA

07:30 - 08:00 **MTE05.02 - Role of Pneumonectomy in N2 Disease**
Paula Ugalde, Canada

MTE06

07:00 - 08:00 Type: Meet the Expert
Title: Symptom Management in Mesothelioma (Ticketed Session)
Track: Mesothelioma

07:00 - 07:30 **MTE06.01 - Role of Pleurectomy in Palliation of Symptoms**
John Edwards, UK

07:30 - 08:00 **MTE06.02 - How to Register Toxicity and Guide Patients**
Liz Darlison, UK

MTE07

07:00 - 08:00 Type: Meet the Expert
Title: Management of Pleural Recurrence (Ticketed Session)
Track: Thymoma/Other Thoracic Malignancies

07:00 - 07:30 **MTE07.01 - From Radiation Oncology Perspective**
Andreas Rimmer, USA

07:30 - 08:00 **MTE07.02 - From Surgical Perspective**
Robert Korst, USA



MTE08

07:00 - 08:00 Type: Meet the Expert
 Title: Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges (Ticketed Session)
 Track: Nursing and Allied Professionals

07:00 - 08:00 **MTE08.01 - Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges**
 Linda Sarna, USA

MTE09

07:00 - 08:00 Type: Meet the Expert
 Title: Management of Advanced Wild-Type Lung Cancer in Special Situations (Ticketed Session)
 Track: Advanced NSCLC

07:00 - 07:30 **MTE09.01 - Evidence Based Management of the Patient over 80**
 Elisabeth Quoix, France

07:30 - 08:00 **MTE09.02 - Management of the PS 2 Patient**
 Joan Schiller, USA

MTE10

07:00 - 08:00 Type: Meet the Expert
 Title: Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous (Ticketed Session)
 Track: Interventional Diagnostics/Pulmonary

07:00 - 08:00 **MTE10.01 - Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous**
 Felix Herth, Germany

PL01

08:15 - 09:45 Type: Plenary Session
 Title: Patients First
 Moderation: Andrea Bezjak, Canada; Paul Bunn Jr., USA

08:15 - 08:25 **PL01.01 - When Breath Becomes Air**

08:25 - 08:40 **PL01.02 - Science that Matters**
 David Carbone, USA

08:40 - 08:55 **PL01.03 - Trials that Matter!**
 Tony Mok, Hong Kong



- 08:55 - 09:10 **PL01.04 - Getting Drugs to Patients Faster: A Global View**
Solange Peters, Switzerland
- 09:10 - 09:25 **PL01.05 - Conquering Lung Cancer - The IASLC Vision**
Giorgio Scagliotti, Italy
- 09:25 - 09:40 **PL01.06 - Patients First**
Tish Vigna, Canada

09:45 - 10:30 Type: Poster Viewing
Title: Poster Viewing - Exhibit Hall

MS01

10:30 - 12:00 Type: Mini Symposium
Title: Cancer Pathways, Targeted Therapy and Resistance

Track: Biology
Moderation: Greg Riely, USA; Wan Lam, Canada

- 10:30 - 10:50 **MS01.01 - Defects of the SWI/SNF OR MYC/MAX Pathways: Effects in Cell Differentiation and Therapeutic Opportunities**
Montse Sanchez-Cespedes, Spain
- 10:50 - 11:10 **MS01.02 - Targeting Negative Feedback Regulators to Hyperactivate Oncogenic Signaling**
Will Lockwood, Canada
- 11:10 - 11:30 **MS01.03 - Stimulating Anti-Tumor Immunity Through Enhancing T-Cell Activation**
Kwok-Kin Wong, USA
- 11:30 - 11:50 **MS01.04 - Addressing Drug Resistance Beyond Kinase Domain Mutations**
Robert Doebele, USA
- 11:50 - 12:00 **MS01.05 - Q&A**

MS02

10:30 - 12:00 Type: Mini Symposium
Title: The Future of IO

Track: Immunocology
Moderation: Yuichiro Ohe, Japan; Rina Hui, Australia

- 10:30 - 10:45 **MS02.01 - What Is/Will Be the Optimal Duration of Therapy with IO?**
David Spigel, USA
- 10:45 - 11:00 **MS02.02 - Combination Therapies: Where Are We in 2018?**
Martin Reck, Germany



- 11:00 - 11:15 **MS02.03 - Next Generation IO in Lung Cancer**
Solange Peters, Switzerland
- 11:15 - 11:30 **MS02.04 - Optimizing Clinical Trial Designs in Immunotherapy**
Vassiliki Papadimitrakopoulou, USA
- 11:30 - 11:45 **MS02.05 - Convincing Policy Makers to Afford Immunotherapy**
Carlos Gil Ferreira, Brazil
- 11:45 - 12:00 **MS02.06 - Q&A**

MS03

10:30 - 12:00 **Type: Mini Symposium**
Title: New Frontiers in Oligometastases
Track: Oligometastatic NSCLC
Moderation: Jyoti Patel, USA; Eric Lim, UK

- 10:30 - 10:45 **MS03.01 - The Biology of Oligometastases: What Have We learned?**
David Palma, Canada
- 10:45 - 11:00 **MS03.02 - Biomarkers in Oligometastatic Patients i. Monitoring Diseases Response - Imaging vs Serum**
Max Diehn, USA
- 11:00 - 11:15 **MS03.03 - Investigations into Alternative Clinical Endpoints for OM Beyond Survival**
Alexander Louie, Canada
- 11:15 - 11:30 **MS03.04 - Treatment of Oligoprogression: Real Progress or False Hope?**
Fiona McDonald, UK
- 11:30 - 11:45 **MS03.05 - Integration of Immunotherapy in the Oligometastatic Paradigm**
Shankar Siva, Australia
- 11:45 - 12:00 **MS03.06 - Q&A**

MS04

10:30 - 12:00 **Type: Mini Symposium**
Title: Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates
Track: Advocacy
Moderation: Carolyn Aldige, USA;

- 10:30 - 10:45 **MS04.01 - Collecting Data in the Real World - How Can Patient Groups Work with Researchers in Defining and Collecting Real-World Evidence?**
Taofeek Owonikoko, USA
- 10:45 - 11:00 **MS04.02 - How Is Lung Cancer Screening Evolving to Be More Efficient and Effective?**
David Baldwin, UK



- 11:00 - 11:15 **MS04.03 - Exploring Smoking Stigma, Negativity and Lung Cancer - What Can Be Done?**
Stefania Vallone, Italy
- 11:15 - 11:30 **MS04.04 - E-Cigarettes - What Do Lung Cancer Advocates Need to Know?**
Matthew Peters, Australia
- 11:30 - 12:00 **MS04.05 - Panel Discussion**

PC01

10:30 - 12:00 Type: Pro-Con Session
Title: Controversies in Mesothelioma
Track: Mesothelioma
Moderation: Nicole Bouchard, Canada; Nico Van Zandwijk, Australia

- 10:30 - 10:45 **PC01.01 - PRO Intrapleural Chemotherapy Is It the Future?**
Isabelle Opitz, Switzerland
- 10:45 - 11:00 **PC01.02 - CON Intrapleural Chemotherapy Is It the Future?**
David Rice, USA
- 11:00 - 11:15 **PC01.03 - PRO IO in Mesothelioma Should Only Be Given on Clinical Trials**
Penny Bradbury, Canada
- 11:15 - 11:30 **PC01.04 - CON in Mesothelioma Should Only Be Given on Clinical Trials**
Evan Alley, USA
- 11:30 - 11:45 **PC01.05 - PRO Radiation Options: Are We SMART Enough?**
John Cho, Canada
- 11:45 - 12:00 **PC01.06 - CON Radiation Options: Are We SMART Enough?**
Charles Simone, USA

ISS07

12:00 - 13:30 Type: Industry Supported Symposia
Title: Symposium Supported by Merck

JTO

12:00 - 13:30 Type: Meet the Editor
Title: Meet the JTO Editor
Moderation: Alex Adjei, USA

- 12:00 - 13:30 **JTO.01 - Meet the JTO Editor**
Alex Adjei, USA



ES01

13:30 - 15:00	Type: Educational Session Title: Advances in Lung Cancer Screening Through Imaging Track: Screening and Early Detection Moderation: Heidi Schmidt, Canada; Denise Aberle, USA
13:30 - 13:50	ES01.01 - Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters Ricardo Avila, USA
13:50 - 14:10	ES01.02 - Image Interpretation and Advances from the Perspective of the Radiologist David Yankelevitz, USA
14:10 - 14:30	ES01.03 - Deep Machine Learning for Screening LDCT Bram Van Ginneken, Netherlands
14:30 - 14:50	ES01.04 - Multi-Phasic Screening - Can We Address Competing Causes of Morbidity * Mortality Such as Coronary Artery Disease and COPD and How to Manage Incidental Findings Rozemarijn Vliegenthart, Netherlands
14:50 - 15:00	ES01.05 - Q&A

MS05

13:30 - 15:00	Type: Mini Symposium Title: Diagnostic Dilemma in Lung Cancer Track: Pathology Moderation: David Hwang, Canada; Johan Botling, Sweden
13:30 - 13:50	MS05.01 - Staging and Pathology of Multiple Lung Nodules Alain Borczuk, USA
13:50 - 14:10	MS05.02 - Defining Invasion in Minimally Invasive Adenocarcinoma Masayuki Noguchi, Japan
14:10 - 14:30	MS05.03 - Tumor Heterogeneity in Lung Cancer Elisabeth Brambilla, France
14:30 - 14:50	MS05.04 - Diagnosis and Classification in Biopsies Andre Moreira, USA
14:50 - 15:00	MS05.05 - Q&A



MS06

13:30 - 15:00 Type: Mini Symposium
 Title: Practical Issues in the Management of Oligometastatic NSCLC
 Track: Oligometastatic NSCLC
 Moderation: Mary Macneil, Canada; Ugo Pastorino, Italy

- 13:30 - 13:45 **MS06.01 - The Role of Radiation in Treating the Mets**
 Hak Choy, USA
- 13:45 - 14:00 **MS06.02 - The Role of Interventional Pulmonology and Radiology**
 Kwun Fong, Australia
- 14:00 - 14:15 **MS06.03 - The Role of Surgical Resection**
 Boris Sepesi, USA
- 14:15 - 14:30 **MS06.04 - Systemic Therapy for Oligomets: Before, During, or After Local Therapies?**
 Ross Camidge, USA
- 14:30 - 14:45 **MS06.05 - The Special Case of Brain Metastases: Systemic Therapy, Radiation or Both?**
 Laurie Gaspar, USA
- 14:45 - 15:00 **MS06.06 - Q&A**

MS07

13:30 - 15:00 Type: Mini Symposium
 Title: Antibody-Drug Conjugates in Advanced NSCLC
 Track: Advanced NSCLC
 Moderation: Normand Blais, Canada;

- 13:30 - 13:50 **MS07.01 - Basic Science**
 David Gerber, USA
- 13:50 - 14:10 **MS07.02 - Pharmacology**
 Christian Rolfo, Belgium
- 14:10 - 14:30 **MS07.03 - Clinical Data**
 Thomas Stinchcombe, USA
- 14:30 - 14:50 **MS07.04 - Future Directions**
 Silvia Novello, Italy
- 14:50 - 15:00 **MS07.05 - Q&A**



MS08

13:30 - 15:00	Type: Mini Symposium Title: Lung Cancer in the Real World
	Track: Treatment in the Real World - Support, Survivorship, Systems Research Moderation: Antoinette Wozniak, USA; Ronan Kelly, USA
13:30 - 13:45	MS08.01 - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies - European Perspective Yolande Lievens, Belgium
13:45 - 14:00	MS08.02 - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies - US Perspective Gideon Blumenthal, USA
14:00 - 14:15	MS08.03 - Sources of Real World Data: Research Designs, Statistical Modelling and Quality Assurance Requirements Mary Redman, USA
14:15 - 14:30	MS08.04 - The ASCO Perspective Bruce Johnson, USA
14:30 - 14:45	MS08.05 - The ESTRO Perspective Umberto Ricardi, Italy
14:45 - 15:00	MS08.06 - Discussion

PC02

13:30 - 15:00	Type: Pro-Con Session Title: Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON
	Track: Small Cell Lung Cancer/NET Moderation: Quincy Chu, Canada; Wilfried Eberhardt, Germany
13:30 - 13:50	PC02.01 - Surgery - PRO Elliot Wakeam, Canada
13:50 - 14:10	PC02.02 - Surgery - CON Cecile Le Pechoux, France
14:10 - 14:30	PC02.03 - BID Radiation - CON Ben Slotman, Netherlands
14:30 - 14:50	PC02.04 - BID Radiation - PRO Jeffrey Bogart, USA
14:50 - 15:00	PC02.05 - Q&A



MS09

15:15 - 16:45 **Type: Mini Symposium**
Title: Tumour Board - Tissue Acquisition and Staging
 Track: Interventional Diagnostics/Pulmonary
 Moderation: Septimiu Murgu, USA; Eric Edell, USA

15:15 - 15:35 **MS09.01 - Cases Prepared by Drs. Edell/Murgu**
 Neal Navani, UK

15:35 - 15:55 **MS09.02 - Cases Prepared by Drs. Edell/Murgu**
 Karin Steinke, Australia

15:55 - 16:15 **MS09.03 - Cases Prepared by Drs. Edell/Murgu**
 Kazuhiro Yasufuku, Canada

16:15 - 16:35 **MS09.04 - Cases Prepared by Drs. Edell/Murgu**

16:35 - 16:45 **MS09.05 - Q&A**

MS10

15:15 - 16:45 **Type: Mini Symposium**
Title: Part Solid Nodules, GGN and STAS
 Track: Treatment of Early Stage/Localized Disease
 Moderation: Paul Van Schil, Belgium; Nir Peled, Israel

15:15 - 15:30 **MS10.01 - Radiographic Differences Between Presumed AIS and MIA**
 Mini Pakkal, Canada

15:30 - 15:45 **MS10.02 - Importance of CT in the Pathologic Assessment of Tumor Sized in Subsolid and Part-Solid Adenocarcinoma**
 Erik Thunnissen, Netherlands

15:45 - 16:00 **MS10.03 - CT Versus Needle Biopsy Assessment Before Resection of Part Solid Nodules**
 Young Tae Kim, Korea

16:00 - 16:15 **MS10.04 - Therapeutic Implications of Spread Through Air Spaces (STAS)**
 William Travis, USA

16:15 - 16:30 **MS10.05 - Should We Resect GGNs**
 Kenji Suzuki, Japan

16:30 - 16:45 **MS10.06 - Q&A**



MS11

15:15 - 16:45	Type: Mini Symposium Title: Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control Track: Prevention and Tobacco Control Moderation: Antoni Rosell, Spain; Li Zhang, China
15:15 - 15:35	MS11.01 - Identifying Consequences of Stigma on Lung Cancer Care Delivery and Patient Outcomes Heidi Hamann, USA
15:35 - 15:55	MS11.02 - Stigma of Tobacco and Lung Cancer: A South American Perspective
15:55 - 16:15	MS11.03 - Prevalence of Perceived Lung Cancer Stigma Among Medical and Nursing Students Jamie Studts, USA
16:15 - 16:35	MS11.04 - Taking a Smoking History in the Context of Lung Cancer Treatment: Missed Opportunities for Stigma-Reducing Empathic Encounters with Throacic Oncologists Peter Harper, UK
16:35 - 16:45	MS11.05 - Q&A

MS12

15:15 - 16:45	Type: Mini Symposium Title: Immunotherapy and RT Track: Treatment of Locoregional Disease - NSCLC Moderation: Yi-long Wu, China; Salama Joseph, USA
15:15 - 15:35	MS12.01 - Biology IO+RT Dirk De Ruyscher, Netherlands
15:35 - 15:55	MS12.02 - Clinical Data Available Feng-Ming (Spring) Kong, USA
15:55 - 16:15	MS12.03 - Ongoing Studies Francoise Mornex, France
16:15 - 16:35	MS12.04 - Implications for Routine Practice Paul Mitchell, Australia
16:35 - 16:45	MS12.05 - Q&A



PC03

- 15:15 - 16:45** **Type: Pro-Con Session**
Title: Controversies in Management of Resectable Thymoma
 Track: Thymoma/Other Thoracic Malignancies
 Moderation: Norihiko Ikeda, Japan; Andrea Bezjak, Canada
- 15:15 - 15:25 **PC03.01 - Post-Operative Radiation Therapy or NOT: PRO**
 Conrad Falkson, Canada
- 15:25 - 15:35 **PC03.02 - Post-Operative Radiation Therapy or NOT: CON**
 Daniel Gomez, USA
- 15:35 - 15:45 **PC03.03 - Discussion**
- 15:45 - 15:55 **PC03.04 - Debate on Standard Surgical Approaches - Minimally Invasive Thymectomy**
 Shaf Keshavjee, Canada
- 15:55 - 16:05 **PC03.05 - Debate on Standard Surgical Approaches - Open Thymectomy**
 Meinoshin Okumura, Japan
- 16:05 - 16:15 **PC03.06 - Discussion**
- 16:15 - 16:25 **PC03.07 - Adjuvant Chemotherapy for Thymic Carcinoma - YES**
 Giulia Pasello, Italy
- 16:25 - 16:35 **PC03.08 - Adjuvant Chemotherapy for Thymic Carcinoma - NO**
 Sukhmani Padda, USA
- 16:35 - 16:45 **PC03.09 - Discussion**

PC04

- 15:15 - 16:45** **Type: Pro-Con Session**
Title: Targeted Therapy for NSCLC
 Track: Targeted Therapy
 Moderation: Zosia Piotrowska, USA; Ben Solomon, Australia
- 15:15 - 15:27 **PC04.01 - Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First)**
 James Chih-Hsin Yang, Taiwan
- 15:27 - 15:39 **PC04.02 - Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First**
 Karen Reckamp, USA
- 15:39 - 15:51 **PC04.03 - Adjuvant Targeted Therapy for pts with Genomic Alterations - Yes**
 Shun Lu, China
- 15:51 - 16:03 **PC04.04 - Adjuvant Targeted Therapy for pts with Genomic Alterations - No**
 Lecia Sequist, USA



16:03 - 16:15 **PC04.05 - NGS/Whole Exome Sequencing for Routine Use**
Daniel Tan, Singapore

16:15 - 16:27 **PC04.06 - Focused Panels for Molecular Profiling for Routine Use**
Fernando Lopez-Rios, Spain

16:27 - 16:45 **PC04.07 - Q&A**

16:45 - 18:00 **Type: Poster Viewing**
Title: Poster Viewing Reception in the Exhibit Hall

ISS08

18:00 - 19:30 **Type: Industry Supported Symposia**
Title: Symposium Supported by Boehringer Ingelheim

20:00 - 22:30 **Type: Networking Opportunity**
Title: Faculty Dinner (By Invitation Only)



Tuesday, September 25, 2018

ISS09

07:00 - 08:00 Type: Industry Supported Symposia
Title: Symposium Supported by Roche

ISS10

07:00 - 08:00 Type: Industry Supported Symposia
Title: Symposium Supported by Medscape: Progressing the Revolution in NSCLC: Questioning the Experts

ISS11

07:00 - 08:00 Type: Industry Supported Symposia
Title: Symposium Supported by Pfizer

MTE11

07:00 - 08:00 Type: Meet the Expert
Title: Biology of Small Cell Lung Cancer (Ticketed Session)
Track: Biology

07:00 - 07:30 MTE11.01 - Novel Therapeutic Targets in SCLC
Julien Sage, USA

07:30 - 08:00 MTE11.02 - Biological Subsets of SCLC
Charles Rudin, USA

MTE12

07:00 - 08:00 Type: Meet the Expert
Title: IO in the Real World - High Risk Populations And Patient Support (Ticketed Session)
Track: Immunocology

07:00 - 07:40 MTE12.01 - Is IO an Option for Patients with Contraindications (Auto-immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)
Andrew Robinson, Canada

07:40 - 08:00 MTE12.02 - How can we Minimize Toxicity for our High Risk Patients?
Massey Nematollahi, Canada



MTE13

07:00 - 08:00 Type: Meet the Expert
Title: Clonal Evolution and Targeted Therapy (Ticketed Session)
Track: Targeted Therapy

07:00 - 07:30 MTE13.01 - Clonal Evolution and Targeted Therapy
Ramaswamy Govindan, USA

07:30 - 08:00 MTE13.02 - Clonal Evolution and Targeted Therapy
Janessa Laskin, Canada

MTE14

07:00 - 08:00 Type: Meet the Expert
Title: Nodule Management (Pro Con Debate and Case Presentations) (Ticketed Session)
Track: Screening and Early Detection

07:00 - 07:30 MTE14.01 - Nodule Management (Pro Con Debate and Case Presentations)
Stephen Lam, Canada

07:30 - 08:00 MTE14.02 - Nodule Management (Pro Con Debate and Case Presentations)
Matthijs Oudkerk, Netherlands

MTE15

07:00 - 08:00 Type: Meet the Expert
Title: Who is Too High Risk for a VATS Resection? (Ticketed Session)
Track: Treatment of Early Stage/Localized Disease

07:00 - 07:30 MTE15.01 - Identifying High Risk Patients: What Makes a Patient Too High Risk for Surgery and Who Decides?
Hisao Asamura, Japan

07:30 - 08:00 MTE15.02 - Who is Too High Risk for a VATS Resection?
Pieter E Postmus, UK

MTE16

07:00 - 08:00 Type: Meet the Expert
Title: What Is Changing in the Management of Pulmonary Neuroendocrine Tumours? (Ticketed Session)
Track: Small Cell Lung Cancer/NET

07:00 - 07:30 MTE16.01 - Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy
Sumitra Thongprasert, Thailand

07:30 - 08:00 MTE16.02 - The Management of Small Cell Lung Cancer following First Line Treatment Failure
Glenwood Goss, Canada



MTE17

07:00 - 08:00 Type: Meet the Expert
 Title: Living with and Beyond Lung Cancer: An Education for Advocates (Ticketed Session)
 Track: Advocacy

07:00 - 08:00 MTE17.01 - Living with and Beyond Lung Cancer: An Education for Advocates
 Aoife McNamara, Ireland; Winfield Boerckel, USA

MTE18

07:00 - 08:00 Type: Meet the Expert
 Title: Case-Based Management of Patients with Inadequate Tissue for Molecular Tests (Ticketed Session)
 Track: Advanced NSCLC

07:00 - 07:30 MTE18.01 - Case-Based Management of Patients with Inadequate Tissue for Molecular Tests
 Benjamin Levy, USA

07:30 - 08:00 MTE18.02 - Case-Based Management of Patients with Inadequate Tissue for Molecular Tests
 Adrian Sacher, Canada

SH01

07:00 - 08:00 Type: Scientific Highlights
 Title: Highlight of the Previous Day Sessions

PL02

08:15 - 09:45 Type: Plenary Session
 Title: Presidential Symposium - Top 4 Abstracts
 Moderation: Frances Shepherd, Canada; Giorgio Scagliotti, Italy; Ming Tsao, Canada

09:55 - 10:25 Type: Exhibit Showcase
 Title: AstraZeneca Exhibit Showcase Session - The Visions and Science for Earlier Treatment

09:55 - 09:55 Developing and Preparing for Earlier Treatments in Lung Cancer
 David Berman, USA

09:55 - 09:55 Early Detection and Monitoring of Lung Cancer
 Carl Barrett, USA



09:45 - 10:30 **Type: Poster Viewing**
Title: Poster Viewing - Exhibit Hall

ES02

10:30 - 12:00 **Type: Educational Session**
Title: Quality Care in Lung Cancer
Track: Nursing and Allied Professionals
Moderation: Pippa Labuc, UK; Nazanin Nouriany, Canada

10:30 - 10:45 **ES02.01 - Expanding PROs in Daily Practice**
Kahren White, Australia

10:45 - 11:00 **ES02.02 - PRO: To Medicate: Managing Breathlessness**
Alexandre Chan, Singapore

11:00 - 11:15 **ES02.03 - CON: Not to Medicate: Managing Breathlessness**
Catherine Granger, Australia

11:15 - 11:30 **ES02.04 - Molecular Testing 101 for Nurses**
Beth Eaby-Sandy, USA

11:30 - 11:45 **ES02.05 - Structured Approach For Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer**
Andrea Serena, Switzerland

11:45 - 12:00 **ES02.06 - Q&A**

GR01

10:30 - 12:00 **Type: Grand Rounds**
Title: Thymic Malignancies Tumor Board
Track: Thymoma/Other Thoracic Malignancies
Moderation: Vincent (Wentao) Fang, China; Giuseppe Giaccone, USA

10:30 - 10:45 **GR01.01 - Pathology**
Anja Roden, USA

10:45 - 11:00 **GR01.02 - Surgical Oncology**
Pier Luigi Filosso, Italy

11:00 - 11:15 **GR01.03 - Surgical Oncology**
David Waller, UK

11:15 - 11:30 **GR01.04 - Medical Oncology**
Nicolas Girard, France

11:30 - 11:45 **GR01.05 - Radiation Oncology**
Anthony Brade, Canada

11:45 - 12:00 **GR01.06 - Discussion**



MS13

10:30 - 12:00	Type: Mini Symposium Title: Novel Mediators of Lung Cancer Metastasis
	Track: Biology Moderation: Oscar Arrieta, Mexico; Kwok-kin Wong, USA
10:30 - 10:45	MS13.01 - Liquid Biopsy-mediated Identification of Metastatic Variants Philip Mack, USA
10:45 - 11:00	MS13.02 - Capicua Inactivation Drives Lung Cancer Metastasis Trevor Bivona, USA
11:00 - 11:15	MS13.03 - Ubiquilin as a Novel Mediator of Lung Cancer Invasion and Metastasis Levi Beverly, USA
11:15 - 11:30	MS13.04 - Tracking the Evolution of Non-Small-Cell Lung Cancer Charles Swanton, USA
11:30 - 11:45	MS13.05 - Discussant David Beer, USA
11:45 - 12:00	MS13.06 - Q&A

MS14

10:30 - 12:00	Type: Mini Symposium Title: IO in Early Stage NSCLC
	Track: Immunocology Moderation: Mark Kris, USA
10:30 - 10:45	MS14.01 - Basic Science Rationale of IO in Early Stage NSCLC? Johan Vansteenkiste, Belgium
10:45 - 11:00	MS14.02 - Adjuvant / Neoadjuvant IO Therapy Julie Brahmer, USA
11:00 - 11:15	MS14.03 - Concerns About IO for the Thoracic Surgeon? Bernward Passlick, Germany
11:15 - 11:30	MS14.04 - IO - New Standards in Stage III NSCLC Rafal Dziadziuszko, Poland
11:30 - 11:45	MS14.05 - Do Biomarkers used in Metastatic Setting Apply in Earlier Stages Naiyer Rizvi, USA
11:45 - 12:00	MS14.06 - Q&A



MS15

10:30 - 12:00	Type: Mini Symposium Title: Disruptive Technology and Lung Cancer Risk Track: Prevention and Tobacco Control Moderation: Eric Bedard, Canada; Doug Arenberg, USA
10:30 - 10:45	MS15.01 - Just Water Vapor? Toxicology Perspectives on Electronic Cigarettes Maciej Goniewicz, USA
10:45 - 11:00	MS15.02 - PRO- Electronic Cigarettes: A Cessation Tool K Michael Cummings, USA
11:00 - 11:15	MS15.03 - CON- Electronic Cigarettes: Not Evidence Based Cessation Alison Wallace, Canada
11:15 - 11:30	MS15.04 - The Rise of Heat-Not Burn Tobacco in Japan: A “Hot” Issue for Tobacco Control Junji Yoshida, Japan
11:30 - 11:45	MS15.05 - Heat-Not-Burn Tobacco: Real Risk Reduction or Industry’s Next Promise Carolyn Dresler, USA
11:45 - 12:00	MS15.06 - Q&A

PC05

10:30 - 12:00	Type: Pro-Con Session Title: Optimizing Clinical Trial Design in NSCLC Track: Advanced NSCLC Moderation: Pilar Garrido, Spain; Luis Ubillos, Uruguay
10:30 - 10:45	PC05.01 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: PFS Mary O’Brien, UK
10:45 - 11:00	PC05.02 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: OS Yu Shyr, USA
11:00 - 11:05	PC05.03 - Discussion
11:05 - 11:20	PC05.04 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - YES Maurice Pérol, France
11:20 - 11:35	PC05.05 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - NO Rathi Pillai, USA
11:35 - 11:40	PC05.06 - Discussion



11:40 - 11:50 **PC05.07 - Let's Not Forget Chemo-Regret**
Patricia Hollen, USA

11:50 - 12:00 **PC05.08 - Discussion**

ISS12

12:00 - 13:30 **Type: Industry Supported Symposia**
Title: Symposium Supported by Novartis: Expert Perspectives on the Management of NSCLC in Clinical Practice: Are Novel Approaches Realistic?

MS16

13:30 - 15:00 **Type: Mini Symposium**
Title: Implementation of Lung Cancer Screening
Track: Screening and Early Detection
Moderation: Garth Nicholas, Canada; Harry Groen, Netherlands

13:30 - 13:45 **MS16.01 - CMS Approved ACR Lung Cancer Screening Registry in the United States**
Ella Kazerooni, USA

13:45 - 14:00 **MS16.02 - NELCIN B3 Screening Program in China**
Qinghua Zhou, China

14:00 - 14:15 **MS16.03 - Population Screening - Canadian Pilot Program in Ontario**
Gail Darling, Canada

14:15 - 14:30 **MS16.04 - National Lung Screening Program in Taiwan**
Pan-Chyr Yang, Taiwan

14:30 - 14:45 **MS16.05 - Optimal Approach to Integrate Smoking Cessation into Screening Program**
Matthew Callister, UK

14:45 - 15:00 **MS16.06 - Q&A**

MS17

13:30 - 15:00 **Type: Mini Symposium**
Title: Life After Lung Cancer: Survivorship
Track: Treatment in the Real World - Support, Survivorship, Systems Research
Moderation: David Dawe, Canada; Jhanelle Gray, USA

13:30 - 13:45 **MS17.01 - Unmet needs and QOL of Lung Cancer Survivors**
Meredith Giuliani, Canada

13:45 - 14:00 **MS17.02 - Financial Toxicity and Out of Pocket Costs**
Bishal Gyawali, Nepal



- 14:00 - 14:15 **MS17.03 - Surveillance & Second Primary Malignancies in Lung Cancer Survivors**
Virginie Westeel, France
- 14:15 - 14:30 **MS17.04 - How Important Is Tobacco Cessation as Part of Lung Cancer Treatment?**
Clarissa Baldotto, Brazil
- 14:30 - 15:00 **MS17.05 - Discussion**

MS18

13:30 - 15:00 Type: Mini Symposium
Title: Management of SCLC Patients Not Represented in Clinical Trials
Track: Small Cell Lung Cancer/NET
Moderation: Jie Wang, China; Everett Vokes, USA

- 13:30 - 13:50 **MS18.01 - Treatment of Patients with Poor Performance Status (ECOG 3-4)**
Luiz Henrique De Lima Araujo, Brazil
- 13:50 - 14:10 **MS18.02 - Treatment of Elderly Patients with SCLC**
Karen Kelly, USA
- 14:10 - 14:30 **MS18.03 - Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma**
Nicolas Marcoux, USA
- 14:30 - 14:50 **MS18.04 - Retreatment with Platinum and Etoposide and Treatment Beyond Second Line**
Charles Butts, Canada
- 14:50 - 15:00 **MS18.05 - Q&A**

MS19

13:30 - 15:00 Type: Mini Symposium
Title: Pulmonary Dilemmas with Immunotherapy
Track: Interventional Diagnostics/Pulmonary
Moderation: Sita Andarini, Indonesia; Luis Raez, USA

- 13:30 - 13:50 **MS19.01 - Drug-Induced Pneumonitis with IO: How worried should we be for our Lung Cancer Patients**
Desiree Hao, Canada
- 13:50 - 14:10 **MS19.02 - What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence**
Chong-Kin Liam, Malaysia
- 14:10 - 14:30 **MS19.03 - Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiopsy for TT Progression**
Kasia Czarnecka, Canada
- 14:30 - 15:00 **MS19.04 - Q&A**



PC06

13:30 - 15:00 **Type: Pro-Con Session**
Title: Controversies in Immunobiomarker Testing
 Track: Pathology
 Moderation: Christian Couture, Canada; Erik Thunnissen, Netherlands

13:30 - 13:50 **PC06.01 - Laboratory Developed Test - PRO**
 Dara Aisner, USA

13:50 - 14:10 **PC06.02 - Laboratory Developed Test - CON**
 Mari Mino-Kenudson, USA

14:10 - 14:30 **PC06.03 - Tumor Mutation Burden - PRO**
 Lynette Sholl, USA

14:30 - 14:50 **PC06.04 - Tumor Mutation Burden - CON**
 Lukas Bubendorf, Switzerland

14:50 - 15:00 **PC06.05 - Q&A**

PC07

13:30 - 15:00 **Type: Pro-Con Session**
Title: The Future of Cytotoxic Chemotherapy in Advanced NSCLC
 Track: Advanced NSCLC
 Moderation: Stephanie Brule, Canada; Terefumi Kato, Japan

13:30 - 13:50 **PC07.01 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - For**
 Suresh Ramalingam, USA

13:50 - 14:10 **PC07.02 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - Against**
 Keunchil Park, Korea

14:10 - 14:30 **PC07.03 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - IO alone**
 Leora Horn, USA

14:30 - 14:50 **PC07.04 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO**
 Federico Cappuzzo, Italy

14:50 - 15:00 **PC07.05 - Q&A**



PC08

13:30 - 15:00	Type: Pro-Con Session Title: The Great Oligometastatic Debates Track: Oligometastatic NSCLC Moderation: Stephen Harrow, UK; Melissa Johnson, USA
13:30 - 13:40	PC08.01 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastases (PRO) Howard (Jack) West, USA
13:40 - 13:50	PC08.02 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastases (CON) Puneeth Iyengar, USA
13:50 - 14:00	PC08.03 - Discussion
14:00 - 14:10	PC08.04 - Debate #2: Optimal Therapy for OM Disease: Thoracic Surgery Should Be the Treatment of Choice Whenever Possible David Jones, USA
14:10 - 14:20	PC08.05 - Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery Matthias Guckenberger, Switzerland
14:20 - 14:30	PC08.06 - Discussion
14:30 - 14:40	PC08.07 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (PRO) Mark Doherty, Canada
14:40 - 14:50	PC08.08 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (CON) Marta Scorsetti, Italy
14:50 - 15:00	PC08.09 - Discussion

ES03

15:15 - 16:45	Type: Educational Session Title: How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy Track: Mesothelioma Moderation: Rolf Stahel, Switzerland; Marc De Perrot, Canada
15:15 - 15:30	ES03.01 - Diagnosis of Mesothelioma Based on Cytology Alone Jennifer Sauter, USA
15:30 - 15:45	ES03.02 - Role of CT Scan to Follow Pleural Plaques Demetris Patsios, Canada
15:45 - 16:00	ES03.03 - When to Repeat Pleural Biopsies Catherine Labbe, Canada



16:00 - 16:15 **ES03.04 - Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease**
Christopher Lee, Canada

16:15 - 16:30 **ES03.05 - Role of Surgery in T0 Mesothelioma**
Seiki Hasegawa, Japan

16:30 - 16:45 **ES03.06 - Q&A**

ES04

15:15 - 16:45 Type: Educational Session
Title: Liquid Biopsies in Lung Cancer
Track: Targeted Therapy
Moderation: Céline Mascaux, France; Sai-Hong Ou, USA

15:15 - 15:35 **ES04.01 - Liquid Biopsies in Lung Cancer**
Ming Tsao, Canada

15:35 - 15:55 **ES04.02 - Mechanisms of Resistance to Targeted Therapy**
Christine Lovly, USA

15:55 - 16:15 **ES04.03 - Overcoming Resistance by Improving Treatment Compliance**
Felipe Gomes, Brazil

16:15 - 16:35 **ES04.04 - Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)**
Enriqueta Felip, Spain

16:35 - 16:45 **ES04.05 - Q&A**

ES05

15:15 - 16:45 Type: Educational Session
Title: Collaboration Between Stakeholders to Improve Lung Cancer Research
Track: Advocacy
Moderation: Bonnie Addario, USA; Toshiyuki Sawa, Japan

15:15 - 15:35 **ES05.01 - Linking the Stakeholders: Can Patient Groups, Clinical Researchers and the Pharmaceutical Industry Collaborate to Accelerate Research?**
Janet Freeman-Daily, USA

15:35 - 15:55 **ES05.02 - Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?**
Andrea Ferris, USA

15:55 - 16:15 **ES05.03 - Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice**
Jesme Fox, UK

16:15 - 16:35 **ES05.04 - Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada**
Christina Sit, Canada



16:35 - 16:45

ES05.05 - Q&A

GR02

15:15 - 16:45

Type: Grand Rounds
Title: Management of N2 NSCLC - A Case Based Discussion
 Track: Treatment of Locoregional Disease - NSCLC
 Moderation: Tomasz Grodzki, Poland; Linda Coate, Ireland

15:15 - 15:25

GR02.01 - Case 1: Single Zone N2 (No Pneumonectomy Necessary)

Ania Wrona, Poland

15:25 - 15:45

GR02.02 - Panel Discussion

David Harpole, USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA

15:45 - 15:55

GR02.03 - Case 2: Multiple N2 Bulky Primary

Megan Daly, USA

15:55 - 16:15

GR02.04 - Panel Discussion

David Harpole, USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA

16:15 - 16:25

GR02.05 - Case 3: Post Operative Management of Incidentally Found N2 Disease

Masaya Yotsukura, Japan

16:25 - 16:45

GR02.06 - Panel Discussion

David Harpole, USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA

MS20

15:15 - 16:45

Type: Mini Symposium
Title: Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC
 Track: Treatment of Early Stage/Localized Disease
 Moderation: Bob Li, Australia; Kazuhiro Yasufuku, Canada

15:15 - 15:30

MS20.01 - Robotic and Innovative Surgery

Wael Hanna, Canada

15:30 - 15:45

MS20.02 - The Future of Stereotactic Ablative Radiotherapy (SABR)

Billy Loo, USA

15:45 - 16:00

MS20.03 - Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe?

Jamie Chافت, USA

16:00 - 16:15

MS20.04 - Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy

Phillippe Broet, France



- 16:15 - 16:30 **MS20.05 - Beyond Surgery - Support of the Surgical Patient**
Katherine Kuhns, USA
- 16:30 - 16:45 **MS20.06 - Less Is More: Segmentectomy in the Management of Early Stage NSCLC**
Shun-ichi Watanabe, Japan

MS21

15:15 - 16:45 Type: Mini Symposium
Title: Giants in Thoracic Oncology
Moderation: Ronald Feld, Canada; Miyako Satouchi, Japan

- 15:15 - 15:25 **MS21.01 - Surgery and its Evolution**
Paul van Schil, Belgium
- 15:25 - 15:35 **MS21.02 - Chemotherapy through the 21st Century**
David Johnson, USA
- 15:35 - 15:45 **MS21.03 - Revolution in Radiation**
Ben Slotman, Netherlands
- 15:45 - 15:55 **MS21.04 - Targeted Therapy - The Second Revolution**
Frances Shepherd, Canada
- 15:55 - 16:05 **MS21.05 - Quality of Life - Are we Paying Enough Attention?**
Richard Gralla, USA
- 16:05 - 16:15 **MS21.06 - Immunotherapy - Sequence or Combination?**
Roy Herbst, USA
- 16:15 - 16:25 **MS21.07 - The Growing Role of Biomarkers in Treatment Selection**
Fred Hirsch, USA
- 16:25 - 16:35 **MS21.08 - Where will we be in 10 years?**
Paul Bunn, Jr., USA
- 16:35 - 16:45 **MS21.09 - Q&A**

16:45 - 18:00 Type: Poster Viewing
Title: Poster Viewing Reception in the Exhibit Hall

16:45 - 17:45 Type: IASLC Business Meeting
Title: IASLC Business Meeting

ISS13



18:00 - 19:30

Type: Industry Supported Symposia
Title: Symposium Supported by AstraZeneca

20:00 - 23:30

Type: Networking Opportunity
Title: Conference Dinner (Ticketed Event)



Wednesday, September 26, 2018

MTE19

07:00 - 08:00 Type: Meet the Expert
 Title: How I Treat Advanced Stage Thymic Malignancy Patients (Ticketed Session)
 Track: Thymoma/Other Thoracic Malignancies

07:00 - 08:00 MTE19.01 - How I Treat Advanced Stage Thymic Malignancy Patients
 Heather Wakelee, USA

MTE20

07:00 - 08:00 Type: Meet the Expert
 Title: Molecular Testing in Small Samples (Ticketed Session)
 Track: Pathology

07:00 - 07:30 MTE20.01 - Molecular Testing in Small Samples
 John Longshore, USA

07:30 - 08:00 MTE20.02 - Molecular Testing in Small Samples
 Jin-Haeng Chung, Korea

MTE21

07:00 - 08:00 Type: Meet the Expert
 Title: Can I Treat Brain Metastasis with Immunotherapy? (Ticketed Session)
 Track: Immunocology

07:00 - 07:30 MTE21.01 - Can I Treat Brain Metastasis with Immunotherapy?
 Sarah Goldberg, USA

07:30 - 08:00 MTE21.02 - Can I Treat Brain Metastasis with Immunotherapy?

MTE22

07:00 - 08:00 Type: Meet the Expert
 Title: Incorporation of Smoking Cessation in Clinical Care (Ticketed Session)
 Track: Prevention and Tobacco Control

07:00 - 07:30 MTE22.01 - Integration of Cessation and Lung Cancer Screening
 Matthew Steliga, USA

07:30 - 08:00 MTE22.02 - Cessation and Clinical Lung Cancer Care
 Jamie Ostroff, USA



MTE23

07:00 - 08:00 **Type: Meet the Expert**
Title: Surgical Considerations Following Induction Therapy for Stage IIIA Disease (Ticketed Session)
 Track: Treatment of Locoregional Disease - NSCLC

07:00 - 07:30 **MTE23.01 - Surgical Considerations Following Induction Therapy for Stage IIIA Disease**
 Eric Vallieres, USA

07:30 - 08:00 **MTE23.02 - Surgical Considerations Following Induction Therapy for Stage IIIA Disease**
 Jonathan Spicer, Canada

MTE24

07:00 - 08:00 **Type: Meet the Expert**
Title: Multiple Lung nodules; Resect, Radiate or Watch? (Ticketed Session)
 Track: Treatment of Early Stage/Localized Disease

07:00 - 07:30 **MTE24.01 - Surgery vs SABR for Early NSCLC**
 Thomas D'amico, USA

07:30 - 08:00 **MTE24.02 - Identifying High Risk Lesions**
 David Ball, Australia

MTE25

07:00 - 08:00 **Type: Meet the Expert**
Title: Enhancing the Care of Your Older Adult Population with Lung Cancer (Ticketed Session)
 Track: Nursing and Allied Professionals

07:00 - 08:00 **MTE25.01 - Enhancing the Care of Your Older Adult Population with Lung Cancer**
 Martine Puts, Canada

MTE26

07:00 - 08:00 **Type: Meet the Expert**
Title: New Paradigms in Symptom Management in Lung Cancer (Ticketed Session)
 Track: Treatment in the Real World - Support, Survivorship, Systems Research

07:00 - 07:30 **MTE26.01 - Onco-Pulmonologist**
 Patricia Rivera, USA

07:30 - 08:00 **MTE26.02 - RN/APN**



MTE27

07:00 - 08:00 **Type: Meet the Expert**
Title: Controversies in Radiotherapy for SCLC (Ticketed Session)
 Track: Small Cell Lung Cancer/NET

07:00 - 08:00 **MTE27.01 - Radiotherapy in ES-SCLC**
 Elizabeth Gore, USA

MTE28

07:00 - 08:00 **Type: Meet the Expert**
Title: Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP (Ticketed Session)
 Track: Interventional Diagnostics/Pulmonary

07:00 - 07:30 **MTE28.01 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP**
 Navneet Singh, India

07:30 - 08:00 **MTE28.02 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP**
 Jason Agulnik, Canada

SH02

07:00 - 08:00 **Type: Scientific Highlights**
Title: Highlight of the Previous Day Sessions

PL03

08:15 - 09:45 **Type: Plenary Session**
Title: Call to Action - Challenges Ahead
 Moderation: Gail Darling, Canada; Nagahiro Saijo, Japan

08:15 - 08:30 **PL03.01 - From Bench to Bedside**
 Charles Swanton, USA

08:30 - 08:45 **PL03.02 - Host Immunity - No Longer a Passive Bystander**
 Julie Brahmer, USA

08:45 - 09:00 **PL03.03 - Beaming into the Future**
 David Palma, Canada

09:00 - 09:15 **PL03.04 - A Cut Above**

09:15 - 09:30 **PL03.05 - It's All In The Tissue**
 Keith Kerr, UK



09:30 - 09:40 **PL03.06 - The Future of Targeted Therapy**
Tetsuya Mitsudomi, Japan

09:45 - 10:30 **Type: Poster Viewing**
Title: Poster Viewing - Exhibit Hall

ES06

10:30 - 12:00 **Type: Educational Session**
Title: Oligometastatic Disease
Track: Oligometastatic NSCLC
Moderation: Renato Martins, USA; Gaetano Rocco, Italy

10:30 - 10:50 **ES06.01 - Current Clinical Trials in Oligometastases**
Anne-Marie Dingemans, Netherlands

10:50 - 11:10 **ES06.02 - Integrating New Systemic Therapy into Trials in OMD**
Sanjay Popat, UK

11:10 - 11:30 **ES06.03 - Developments in SBRT in the Oligometastatic Paradigm in NSCLC**
Patrick Cheung, Canada

11:30 - 11:50 **ES06.04 - Surgical Considerations in OMD**
Jessica Donington, USA

11:50 - 12:00 **ES06.05 - Q&A**

MS22

10:30 - 12:00 **Type: Mini Symposium**
Title: Biology of the Lung and Lung Cancer
Track: Biology
Moderation: Matthew Meyerson, USA; Geoffrey Liu, Canada

10:30 - 10:45 **MS22.01 - Lung Development and Stem Cells**
Carla Kim, USA

10:45 - 11:00 **MS22.02 - Epigenetic Alterations in Lung Cancer Development**
Wan Lam, Canada

11:00 - 11:15 **MS22.03 - Non-Coding RNA in Lung Cancer**
Sven Diederichs, Germany

11:15 - 11:30 **MS22.04 - Genomics of Resistance and Response in Lung Cancer**
Marc Ladanyi, USA

11:30 - 11:45 **MS22.05 - Inflammation in Lung Cancer**
Katerina Politi, USA



11:45 - 12:00 **MS22.06 - Transcriptomic-Metabolomic Reprograming as Resistant Mechanism**
Patrick Ma, USA

MS23

10:30 - 12:00 **Type: Mini Symposium**
Title: What's New in Targeted Therapy?
Track: Targeted Therapy
Moderation: Vera Hirsh, Canada; Alexander Drilon, USA

10:30 - 10:45 **MS23.01 - Novel Combinations of Targeted Therapies**
Pasi Jänne, USA

10:45 - 11:00 **MS23.02 - Emerging or Rare Targets - Fusions, Mutational Burden Etc**
Luis Paz-Ares, Spain

11:00 - 11:15 **MS23.03 - Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onco Perspectives)**
Marina Garassino, Italy

11:15 - 11:30 **MS23.04 - Targeting Driver Oncogenes in Stage 1-3 NSCLC**
Helena Yu, USA

11:30 - 11:45 **MS23.05 - Role of Immunotherapy in Patients with Molecular Driven NSCLC**
Benjamin Besse, France

11:45 - 12:00 **MS23.06 - Q&A**

MS24

10:30 - 12:00 **Type: Mini Symposium**
Title: Global Perspectives on Tobacco Control
Track: Prevention and Tobacco Control
Moderation: Rui, Haddad, Brazil; Desmond Carney, Ireland

10:30 - 10:45 **MS24.01 - Tobacco Control Impacting the Effectiveness and Cost of Cancer Care**
Graham Warren, USA

10:45 - 11:00 **MS24.02 - Legal Action Against the Tobacco Industry in Europe**
Paul Baas, Netherlands

11:00 - 11:15 **MS24.03 - The Importance of Physician Involvement in Tobacco Control**
Jacek Jassem, Poland

11:15 - 11:30 **MS24.04 - Challenges of Tobacco Control in China**
Caicun Zhou, China

11:30 - 11:45 **MS24.05 - Money Matters: Portfolio Divestment as a Means of Tobacco Control**
Bronwyn King, Australia

11:45 - 12:00 **MS24.06 - Q&A**



MS25

10:30 - 12:00	Type: Mini Symposium Title: Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes Track: Mesothelioma Moderation: Dean Fennell, UK; Aaron Mansfield, USA
10:30 - 10:45	MS25.01 - Impact of Tumor Volume on Outcome: What Are the Limitations? Anna Nowak, Australia
10:45 - 11:00	MS25.02 - How Should P16, BAP1, and NF2 Mutations Be Integrated in Therapeutic Algorithms? Francoise Galateau-Salle, France
11:00 - 11:15	MS25.03 - Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis Thomas John, Australia
11:15 - 11:30	MS25.04 - Biomarkers in Clinical Practice: Is It Prime Time? Harvey Pass, USA
11:30 - 11:45	MS25.05 - Targeting the Micro-RNA: A New Therapeutic Venture Nick Pavlakis, Australia
11:45 - 12:00	MS25.06 - Q&A

MS26

10:30 - 12:00	Type: Mini Symposium Title: From Textbook to Practice Around the World Track: Treatment in the Real World - Support, Survivorship, Systems Research Moderation: Jarushka Naidoo, USA; Fabio Moraes, Brazil
10:30 - 10:45	MS26.01 - Translation of Clinical Data to Real World - Asia Dae Ho Lee, Korea
10:45 - 11:00	MS26.02 - Translation of Clinical Data to Real World - North America Cheryl Ho, Canada
11:00 - 11:15	MS26.03 - Translation of Clinical Data to Real World - Europe Fabrice Barlesi, France
11:15 - 11:30	MS26.04 - Translation of Clinical Data to Real World - Latin America/Africa Gilberto De Lima Lopes, USA
11:30 - 12:00	MS26.05 - Panel Discussion



MS27

10:30 - 12:00	Type: Mini Symposium Title: Therapeutic Implications of Staging Issues Track: Treatment of Early Stage/Localized Disease Moderation: Janet Edwards, Canada; Masaaki Ito, Japan
10:30 - 10:45	MS27.01 - Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications Raymond Osarogiagbon, USA
10:45 - 11:00	MS27.02 - Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary? Anand Swaminath, Canada
11:00 - 11:15	MS27.03 - Multiple Lung Nodules: M1, T4 or T3? Are They Really Different? Frank Detterbeck, USA
11:15 - 11:30	MS27.04 - Therapeutic Implications of AJCC 8th Edition T1 Subsets Laura Donahoe, Canada
11:30 - 11:45	MS27.05 - The Future of Precision Therapy for Localized Lung Cancer Takashi Seto, Japan
11:45 - 12:00	MS27.06 - Q&A

PC09

10:30 - 12:00	Type: Pro-Con Session Title: Approaches to Management of Advanced NSCLC Track: Advanced NSCLC Moderation: Gwyn Bebb, Canada; Yasushi Goto, Japan
10:30 - 10:45	PC09.01 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Early Qing (Jolie) Zhou, China
10:45 - 11:00	PC09.02 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Delayed Walter Curran Jr., USA
11:00 - 11:15	PC09.03 - Discussion
11:15 - 11:30	PC09.04 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - NSCLC Noemi Reguart, Spain
11:30 - 11:45	PC09.05 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC Scott Laurie, Canada
11:45 - 12:00	PC09.06 - Discussion



12:00 - 13:30 **Type: Poster Viewing**
Title: Poster Viewing - Exhibit Hall

ISS14

12:00 - 13:30 **Type: Industry Supported Symposia**
Title: Symposium Supported by AbbVie: New Frontiers in Lung Cancer

13:30 - 15:00 **Type: Lectureship Award Session**
Title: IASLC Lectureship Award Session

ES07

13:30 - 15:00 **Type: Educational Session**
Title: Beyond the Diagnosis - Collaborative Care for Change

Track: Nursing and Allied Professionals
Moderation: Maria Guerin, UK; Diane Zawisza, Canada

- 13:30 - 13:50 **ES07.01 - A Moment in Time for the Unplanned Conversations**
Kelly Mcguigan, Canada
- 13:50 - 14:00 **ES07.02 - Special Needs and Wellness in Lung Cancer Patients - Australian Perspective**
Maria Ftanou, Australia
- 14:00 - 14:10 **ES07.03 - Special Needs and Wellness in Lung Cancer Patients - European Perspective**
Rossie Navon, Israel
- 14:10 - 14:30 **ES07.04 - Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma**
Lisa Carter-Harris, USA
- 14:30 - 14:50 **ES07.05 - Research Update: Patient's Perspective on Living with Malignant Pleural Mesothelioma**
Angela Tod, UK
- 14:50 - 15:00 **ES07.06 - Q&A**

ES08

13:30 - 15:00 **Type: Educational Session**
Title: The Pathologist - An Essential Member of the Patient Care Team

Track: Pathology
Moderation: Claudia Poleri, Argentina

13:30 - 13:50 **ES08.01 - Targeted Therapy**
Yasushi Yatabe, Japan



- 13:50 - 14:10 **ES08.02 - Immunotherapy**
Sylvie Lantuejoul, France
- 14:10 - 14:30 **ES08.03 - Mesothelioma, Thymic Epithelial Tumors and Others**
Andrew Nicholson, UK
- 14:30 - 14:50 **ES08.04 - Neoadjuvant Therapy**
Ignacio Wistuba, USA
- 14:50 - 15:00 **ES08.05 - Q&A**

MS28

13:30 - 15:00 Type: Mini Symposium
Title: IO Combinations in Advanced NSCLC
Track: Immunocology
Moderation: Corey Langer, USA

- 13:30 - 13:45 **MS28.01 - Understanding the Rationale for Combining IO Agents**
Edward Garon, USA
- 13:45 - 14:00 **MS28.02 - Combination IO+IO**
Myung-ju Ahn, Korea
- 14:00 - 14:15 **MS28.03 - Combinatorial IO + Chemo**
Roselyn Juergens, Canada
- 14:15 - 14:30 **MS28.04 - Combination with Targeted Therapies**
Ross Soo, Singapore
- 14:30 - 14:45 **MS28.05 - Combining IO with Radiation**
Corinne Faivre-Finn, UK
- 14:45 - 15:00 **MS28.06 - Q&A**

MS29

13:30 - 15:00 Type: Mini Symposium
Title: Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers
Track: Screening and Early Detection
Moderation: John Goffin, Canada; Betty Tong, USA

- 13:30 - 13:45 **MS29.01 - Assessment of Risk Prediction Algorithms for Entry into Screening Programs**
Martin Tammemagi, Canada
- 13:45 - 14:00 **MS29.02 - Defining Screening Frequency & Duration Using Risk Prediction Algorithms and CT Image Findings**
Kevin Ten Haaf, Netherlands
- 14:00 - 14:15 **MS29.03 - Polygenic Risk Score for Risk Assessment**
Rayjean Hung, Canada



- 14:15 - 14:30 **MS29.04 - LuCID Exhaled Breath Analysis**
Marc Van Der Schee, UK
- 14:30 - 14:45 **MS29.05 - Early Detection Biomarker Development: Is Success on the Horizon?**
Peter Mazzone, USA
- 14:45 - 15:00 **MS29.06 - Q&A**

MS30

- 13:30 - 15:00** **Type: Mini Symposium**
Title: Modern Day RT in LA NSCLC: Where Is the Evidence?
Track: Treatment of Locoregional Disease - NSCLC
Moderation: Fiona Hegi-Johnson, Australia; Yuko Nakayama, Japan

- 13:30 - 13:45 **MS30.01 - Overview of RT Technology in LA NSCLC (IMRT, VMAT, IGRT)**
Gerard Hanna, Ireland
- 13:45 - 14:00 **MS30.02 - What Evidence Is Available to Support RT Technology in LA NSCLC (including Protons)?**
Yong Chan Ahn, Korea
- 14:00 - 14:15 **MS30.03 - What Evidence Is Available to Support RT Treatment Intensification in LA NSCLC?**
Jeffrey Bradley, USA
- 14:15 - 14:30 **MS30.04 - Perspective**
Maria Werner-Wasik, USA
- 14:30 - 14:45 **MS30.05 - Nutritional Management During Radical Radiotherapy**
Rhys White, UK
- 14:45 - 15:00 **MS30.06 - Q&A**

MS31

- 13:30 - 15:00** **Type: Mini Symposium**
Title: Clinical Science in Mesothelioma
Track: Mesothelioma
Moderation: Haining Yang, US; Marc de Perrot, Canada

- 13:30 - 13:45 **MS31.01 - Mechanisms and Targets for BAP1 Activity**
Michele Carbone, USA
- 13:45 - 14:00 **MS31.02 - Clinical Implementation of BAP1 Inhibitors**
Paul Baas, Netherlands
- 14:00 - 14:15 **MS31.03 - Targeting the Hippo Pathway**
David Jablons, USA
- 14:15 - 14:30 **MS31.04 - CAR-T and ADC's in MPM**
Prasad Adusumilli, USA



14:30 - 14:45 **MS31.05 - Vaccination and Antibody-Based Therapy in Mesothelioma**
Joachim Aerts, Netherlands

14:45 - 15:00 **MS31.06 - Q&A**

MS32

13:30 - 15:00 Type: Mini Symposium
Title: SCLC - From Benchside to Bedside - Clinical Science Session
Track: Small Cell Lung Cancer/NET
Moderation: Alex Adjei, USA

13:30 - 13:45 **MS32.01 - Genetic Mouse Models (GEMMS)**
Trudy Oliver, USA

13:45 - 14:00 **MS32.02 - Patient Derived Models (PDX & CTC-Derived)**
Anna Farago, USA

14:00 - 14:15 **MS32.03 - Liquid Biopsies for Drug Development in SCLC**
Caroline Dive, UK

14:15 - 14:30 **MS32.04 - Molecular Phenotypes of SCLC**
Adi Gazdar, USA

14:30 - 14:45 **MS32.05 - Targeting DNA Damage and Repair**
Lauren Byers, USA

14:45 - 15:00 **MS32.06 - Epigenetic Targets**
John Poirier, USA

PL04

15:15 - 16:30 Type: Plenary Session
Title: Take Action - Key Messages from WCLC 2018 and Goals for 2019
Moderation: Natasha Leighl, Canada; Robert Pirker, Austria

15:15 - 15:20 **PL04.01 - Medical Oncology**
David R Gandara, USA

15:20 - 15:25 **PL04.02 - Pathology**
Fred Hirsch, USA

15:25 - 15:30 **PL04.03 - Surgery**
Ramon Rami-Porta, Spain

15:30 - 15:35 **PL04.06 - Radiation Oncology**
Jose Belderbos, Netherlands

15:35 - 15:40 **PL04.04 - Americas**
Clarissa Mathias, Brazil



15:40 - 15:45	PL04.05 - Asia Pacific Michael Boyer, Australia
15:45 - 16:25	PL04.07 - Discussion and Q&A
16:25 - 16:30	PL04.08 - Invitation to WCLC 2019 Barcelona, Spain